ASH 2020 | RESPONSE-2: 5-year follow-up of second-line ruxolitinib therapy for PV
Srdan Verstovek, MD, PhD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX shares the findings of the 5-year follow-up of the Phase III RESPONSE-2 trial (NCT02038036) in polycythemia vera (PV). The trial compared ruxolitinib (RUX), a JAK inhibitor, to best available therapy in hydroxyurea resistant/intolerant PV patients. The results showed that RUX was superior when compared to best available therapy, with regards to durable HCT control, complete hematologic response rate and PV-associated symptoms. The 5-year follow-up results show that these responses are durable. It was well tolerated, with fewer thromboembolic events than with best available therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Srdan Verstovsek, MD, PhD, has received research support for clinical studies from Incyte, Roche, NS, Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Abbvie, Blueprint Medicines Corp., Novartis, Sierra Oncology, PharmaEssentia, Constellation, Ital Pharma, Protagonist and Kartos.
